CollaGenex Pharmaceuticals, Inc. Announces Expiration of the Hart-Scott-Rodino Waiting Period for Merger with Galderma Pharma S.A.

NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired in connection with the pending merger of CollaGenex with an affiliate of Galderma Pharma S.A.. As previously announced, the merger has been structured as a two-step transaction involving a cash tender offer for all outstanding shares of CollaGenex common stock followed by a cash merger in which Galderma would acquire any remaining shares of CollaGenex common stock.